1 / 1

Supplementary Fig S11

Disease-free survival ( p =0.02). Overall survival ( p =0.011). Supplementary Fig. S11. Kaplan-Meir analysis comparing patients with chemosensitive with chemoresistant tumors for overall survival and disease free survival

louis
Download Presentation

Supplementary Fig S11

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Disease-free survival (p=0.02) Overall survival (p=0.011) Supplementary Fig. S11. Kaplan-Meir analysis comparing patients with chemosensitive with chemoresistant tumors for overall survival and disease free survival Analysis of survival data of the patients in our TMA samples with TAX and EPI resistance did indeed show statistical significant correlation. There were a total of 57 patients who had been recorded to have received either neoadjuvant or adjuvant chemotherapy. Chemoresistance was defined as those who received chemotherapy, and subsequently developed local relapse or distant metastases. Chemosensitivity was defined as those who remained disease free on follow-up having received chemotherapy. Kaplan-Meir analysis comparing patients with chemosensitive with chemoresistant tumors for overall survival and disease free survival showed there was significant association between chemoresistance with poor disease-free survival (p=0.02 ) and with overall survival (p=0.011). SupplementaryFigS11

More Related